Objective To develop a population pharmacokinetic/pharmacodynamic model describing the
relationship between motesanib exposure and tumor response in a phase 2 study of …

Purpose To develop a modeling framework that simulates clinical endpoints (objective
response rate and progression-free survival) to support development of motesanib. The …

Purpose This phase II study investigated the efficacy and tolerability of motesanib, an
investigational, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2 …

Context: Antiangiogenic therapies have shown potential in the treatment of advanced thyroid
cancer, but it is uncertain which patients are most likely to benefit from therapy. Objective …

Background The expression of vascular endothelial growth factor (VEGF) is characteristic of
differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor …

6017 Background: This phase 2 study evaluated the safety and efficacy of AMG 706, an oral,
investigational multikinase (MKI) inhibitor with antiangiogenic and direct antitumor activity …

Abstract Background and Objectives Cabozantinib is a tyrosine kinase inhibitor approved in
the USA and EU for the treatment of patients with progressive, metastatic medullary thyroid …

The aim of this open-label phase 1b study was to assess the safety and pharmacokinetics of
motesanib in combination with gemcitabine in patients with advanced solid tumours. Eligible …

Background: Medullary thyroid cancer (MTC) is frequently associated with mutations in the
tyrosine kinase Ret and with increased expression of vascular endothelial growth factor …

Selumetinib (AZD6244, ARRY‐142886), a mitogen activated protein kinases (MEK1 and 2)
inhibitor, has been granted orphan drug designation for differentiated thyroid cancer. The …